AI vs. Offshore: The Real Cost Comparison

Oscar Fesoterodine (Toviaz) (PG102) Form


Fesoterodine (Toviaz) for Overactive Bladder in Adults

Indications

(149224) Is the patient 18 years or older? 
(149225) Does the patient have a documented diagnosis of overactive bladder (OAB) with symptoms of urinary incontinence, urgency, and frequency? 
(149226) Has the patient tried and failed three of the formulary extended-release alternatives (darifenacin ER, oxybutynin ER, tolterodine ER, trospium ER) for at least a 30 day duration each? 
(149227) Is chart documentation provided to validate the above-listed requirements? 

Fesoterodine (Toviaz) for Neurogenic Detrusor Overactivity in Pediatric Patients

Indications

(149228) Is the patient 6 years or older? 

YesNoN/A
YesNoN/A
YesNoN/A

Sign up to see the rest of the questions

Unlock the remaining questions and the full coverage workflow.

Sign up for free
Effective Date

NA

Last Reviewed

09/2021

Original Document

  Reference



Fesoterodine (Toviaz) is an anticholinergic medication used as a urinary antispasmodic agent. It antagonizes acetylcholine at muscarinic cholinergic receptors, relaxing bladder smooth muscle, decreasing detrusor pressure, and reducing bladder contractions. Fesoterodine is often used in treating overactive bladder (OAB), urinary incontinence, and urinary urgency. Initial treatments for these conditions usually include lifestyle modifications, pelvic floor exercises in women, bladder training, and management of urinary symptom-causing factors. If non-drug treatments fail to provide sufficient symptom improvement, urinary antispasmodic agents like fesoterodine may be employed. It takes up to 12 weeks for these medications to demonstrate effectiveness.

Fesoterodine is FDA-approved for treating OAB in adults and neurogenic detrusor overactivity (NDO) in pediatric patients aged 6 and above who weigh 25 kilograms or more. The drug is available as extended-release tablets, which can help reduce side effect occurrence.

Definitions
  • \